Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

Conclusion Replacing ZA with denosumab is a risk factor for developing ONJ. Both bisphosphonate binding to the bone and RANKL inhibition could additively increase the risk of developing ONJ. We bring the replacement of ZA with denosumab to the attention of clinical oncologists.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research